Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
Rang în acțiuni #25865
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Preț acțiune
$1.21
Capitalizare de piață
$45.55M
Schimbare (1 zi)
-2.43%
Schimbare (1 an)
-34.60%
Țară
US
Tranzacționează Metagenomi, Inc. Common Stock (MGX)

Categorie

Raport P/B pentru Metagenomi, Inc. Common Stock (MGX)
Raport P/B la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Metagenomi, Inc. Common Stock, raportul P/B actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/B de 0.
Istoricul raportului P/B pentru Metagenomi, Inc. Common Stock din 2026 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US